9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Prostate cancer is the most prevalent urogenital malignancy. However, despite initial disease control using androgen deprivation, most of patients eventually develop progressive disease that is resistant to further hormone manipulation. For these patients with castration-resistant prostate cancer (CRPC), and particularly patients with metastatic disease, options have been limited, and prognosis is grim. However, as newer regimens and agents become available, higher rates of objective and biochemical response are being achieved, providing renewed hope for the management of these patients. With the aim of facilitating the treatment of these patients, the Spanish Oncology Genitourinary Group (SOGUG) has issued a series of the recommendations which have been collected in this review. Each recommendation is accompanied by the appropriate level of evidence and grade of recommendation on the basis of the characteristics of the data available.

          Related collections

          Author and article information

          Journal
          Crit. Rev. Oncol. Hematol.
          Critical reviews in oncology/hematology
          Elsevier BV
          1879-0461
          1040-8428
          Sep 2012
          : 83
          : 3
          Affiliations
          [1 ] Instituto Valenciano de Oncología (IVO), Valencia, Spain. macliment@fivo.org
          Article
          S1040-8428(12)00003-0
          10.1016/j.critrevonc.2012.01.002
          22285697
          3d16094e-669c-4913-898f-9da563380ac5
          History

          Comments

          Comment on this article